by National Cancer Institute Left frame: Normally, tumor cells (purple) evade the immune system’s T cells (pink) by expressing a checkpoint protein known as PD-L1. Right frame: Atezolizumab (Tecentriq) binds to PD-L1 and blocks it from binding to another checkpoint protein, PD-1. This helps T cells regain their ability to kill tumor cells. Credit: Adapted...
Tag: <span>Atezolizumab</span>
Atezolizumab translates into survival benefit for bladder cancer patients with ctDNA positivity
by European Association of Urology Credit: Unsplash/CC0 Public Domain Researchers who treated a group of post-surgery bladder cancer patients with the immunotherapy drug atezolizumab have found that patients whose blood contained circulating tumor DNA (ctDNA), responded very well to the treatment. The study is presented today at the European Association of Urology annual congress (EAU22),...
Combination of chemo and immunotherapy is shown to work against metastatic bladder cancer
by The Mount Sinai Hospital A clinical trial led by Mount Sinai researchers has showed for the first time that combining chemotherapy and immunotherapy can slow down metastatic bladder cancer. The trial also showed that immunotherapy alone may be an option for a subset of patients with metastatic bladder cancer if their tumor expresses a...
New treatment extends lives of people with most common type of liver cancer
by University of California, Los Angeles For the first time in over a decade, scientists have identified a first-line treatment that significantly improves survival for people with hepatocellular carcinoma, the most common type of liver cancer. Researchers found that the combination of atezolizumab, an immunotherapy drug that boosts the body’s natural defenses, and bevacizumab, an...
Some lung cancer patients benefit from immunotherapy even after disease progression
Some advanced lung cancer patients benefit from immunotherapy even after the disease has progressed as evaluated by standard criteria, according to research presented at the European Lung Cancer Conference (ELCC).1 The findings pave the way for certain patients to continue treatment if the disease is not progressing according to new, more specific, criteria. The Response Evaluation...